Get the Stockscreener App
6.09
1.00%
0.06
After Hours:
6.15
0.06
+0.99%
Sagimet Biosciences Inc stock is traded at $6.09, with a volume of 272.07K.
It is up +1.00% in the last 24 hours and up +2.18% over the past month.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
See More
Previous Close:
$6.03
Open:
$5.99
24h Volume:
272.07K
Relative Volume:
0.48
Market Cap:
$198.06M
Revenue:
-
Net Income/Loss:
$-29.25M
P/E Ratio:
-5.1349
EPS:
-1.186
Net Cash Flow:
$-22.80M
1W Performance:
-3.03%
1M Performance:
+2.18%
6M Performance:
-40.53%
1Y Performance:
+31.82%
1-Day Range:
$5.9274
$6.14
1-Week Range:
$5.88
$6.60
52-Week Range:
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Name
Sagimet Biosciences Inc
Sector
Industry
Phone
(650) 561-8600
Address
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
6.09 | 196.11M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Initiated | Wedbush | Outperform |
| Aug-07-25 | Resumed | H.C. Wainwright | Buy |
| Jul-24-25 | Initiated | Canaccord Genuity | Buy |
| Dec-06-24 | Initiated | Oppenheimer | Outperform |
| Nov-12-24 | Initiated | UBS | Buy |
| Jun-28-24 | Downgrade | Goldman | Buy → Neutral |
| May-02-24 | Initiated | H.C. Wainwright | Buy |
| Mar-25-24 | Initiated | Leerink Partners | Outperform |
| Aug-08-23 | Initiated | Goldman | Buy |
| Aug-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Aug-08-23 | Initiated | Piper Sandler | Overweight |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
View All
Sagimet Biosciences Inc Stock (SGMT) Latest News
Is Sagimet Biosciences Inc stock influenced by commodity pricesWeekly Profit Analysis & Reliable Breakout Forecasts - baoquankhu1.vn
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Sagimet Biosciences enters global license agreement with TAPI - MSN
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) Shares Down 0.5%Here's Why - MarketBeat
Trend Review: Can Sagimet Biosciences Inc deliver alphaWeekly Market Outlook & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Will Sagimet Biosciences Inc stock keep outperforming rivalsJuly 2025 WrapUp & Fast Entry High Yield Tips - Bộ Nội Vụ
Death Cross: Can Sagimet Biosciences Inc stock reach 100 price targetPortfolio Risk Summary & High Return Trade Opportunity Guides - Bộ Nội Vụ
Sagimet Biosciences: Advancing FASN Inhibitor Pipeline and Multi-Indication Opportunities Support Buy Rating and $26 Target - TipRanks
Why Sagimet Biosciences Inc. stock remains on watchlistsJuly 2025 Recap & AI Powered Market Entry Strategies - Улправда
After-Hours Biotech Gainers: RVMD Soars On Merck Deal Talks Reports, SXTC, KALV, SGMT Rally - RTTNews
How Sagimet Biosciences Inc. stock performs in stagflationJuly 2025 Fed Impact & Verified Short-Term Plans - Улправда
Why retail investors favor Sagimet Biosciences Inc. stockQuarterly Investment Review & AI Based Buy and Sell Signals - Улправда
Why Sagimet Biosciences Inc. stock could be next big winnerRisk Management & Reliable Breakout Forecasts - Улправда
Can Sagimet Biosciences Inc. stock beat market expectations this quarterJuly 2025 PreEarnings & AI Driven Price Forecasts - Улправда
Published on: 2026-01-08 19:16:00 - Улправда
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference - The Manila Times
Study links experimental drug to improved liver fibrosis in MASH patients - Stock Titan
Falcon Technoprojects India Limited Chart Enters High Volatility ZoneTake Profit Strategies & Fast Growing Trading Ideas - earlytimes.in
Sagimet Biosciences Inc. (SGMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
We're Hopeful That Sagimet Biosciences (NASDAQ:SGMT) Will Use Its Cash Wisely - Yahoo Finance
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Disc Medicine (IRON) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $26 - 富途牛牛
Sagimet rises as licensing deal with Teva unit targets Madrigal drug - MSN
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts - TipRanks
Why Sagimet Biosciences Inc. stock could rally in 2025Gap Up & Verified Entry Point Detection - Улправда
Sagimet Biosciences (NASDAQ:SGMT) Stock Price Up 5.4%Still a Buy? - MarketBeat
Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market (SGMT) - Seeking Alpha
Can Sagimet Biosciences Inc. stock maintain growth trajectoryJuly 2025 Levels & Daily Entry Point Trade Alerts - DonanımHaber
Sagimet reports positive Phase 1 results for MASH combination therapy By Investing.com - Investing.com Australia
How Sagimet Biosciences Inc. stock performs in high volatility marketsPrice Action & Low Volatility Stock Suggestions - DonanımHaber
Guidance Update: Why Sagimet Biosciences Inc. stock could be next big winner - Улправда
How Sagimet Biosciences Inc. (0O2) stock compares with top peersWeekly Investment Summary & Daily Chart Pattern Signals - Улправда
Investment Review: Why Sagimet Biosciences Inc. stock could be next big winnerMarket Sentiment Review & Fast Exit and Entry Trade Guides - Улправда
Sagimet Highlights Positive MASH Combo Data and Pipeline Progress - TipRanks
Sagimet reports positive Phase 1 results for MASH combination therapy - Investing.com India
Sagimet Biosciences Announces Positive Phase 1 PK Trial Results - TradingView — Track All Markets
[8-K] Sagimet Biosciences Inc. Reports Material Event | SGMT SEC FilingForm 8-K - Stock Titan
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination - The Manila Times
Sagimet Biosciences Announces Positive Results from the - GlobeNewswire
Sagimet Biosciences (Nasdaq:SGMT) Secures Global License for Resmetirom API in Combination Program - Kalkine Media
Strategic Licensing and Pipeline Advancements Drive Buy Rating for Sagimet Biosciences - TipRanks
Sagimet Biosciences Signs License Agreement With Teva Subsidiary for Resmetirom Development - marketscreener.com
TEVA's Subsidiary Grants License to Sagimet for Innovative Drug Development - GuruFocus
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program - The Manila Times
Sagimet Biosciences Inc Enters License Agreement with TAPI - TradingView — Track All Markets
Sagimet Biosciences (NASDAQ: SGMT) signs TAPI deal for resmetirom API combo - Stock Titan
Sagimet Biosciences and TAPI Announce Global License - GlobeNewswire
Sagimet Biosciences Inc Stock (SGMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):